RxDoctor Payments Data

March Seabrook, MD

Gastroenterology · West Columbia, SCNPI 1689602740

Payments from drug & device makers

$9,460in general payments, 2019–2025

Across 549 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$883
  • Johnson & Johnson$752
  • Pfizer$569
  • Bristol Myers Squibb$410
  • Takeda Pharmaceuticals U.S.A., Inc.$349
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$9,35399%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,460 in reported general payments places this provider in the 70th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$301,111
Medicare patients
1,179
Services billed
3,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$428,200
SucraidSacrosidase14$196,972
CreonLipase/Protease/Amylase39$136,448
LinzessLinaclotide26$26,290
Mesalamine58$24,624
ZenpepLipase/Protease/Amylase11$21,253
Dexlansoprazole DrDexlansoprazole33$8,481
Pantoprazole Sodium464$7,130
TrulancePlecanatide12$6,739
CholestyramineCholestyramine (With Sugar)24$2,470
Omeprazole143$2,110
Esomeprazole Magnesium33$1,277
Dicyclomine Hcl49$968
Sucralfate39$583
Hydrocortisone25$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$236$196,97214 claims
AbbVieCreon, Linzess$4,097$162,73865 claims
Aimmune Therapeutics, Inc.Zenpep$119$21,25311 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$883$6,73912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in West Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →